ESMO 2018 | The role of cabozantinib in renal cell carcinoma
Over the years, the treatment of renal cell carcinoma (RCC) has evolved rapidy. Bradley McGregor, MD, of the Dana-Farber Cancer Institute, Boston, MA, provides an overview of the transition to immunotherapy from non-specific treatments for RCC. Dr McGregor focuses particularly on the role of cabozantinib in the first- and second-line treatment of RCC, highlighting promising results from recent clinical trials. This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.
Get great new content delivered to your inboxSign up